28385075|t|Propensity Score Matched Comparison of Partial to Whole Gland Cryotherapy for Intermediate-Risk Prostate Cancer: An analysis of the COLD registry data
28385075|a|To compare the oncological and functional outcomes of partial versus whole - gland cryotherapy for men with intermediate-risk prostate cancer. Men with intermediate-risk prostate cancer treated with primary prostate cryotherapy from 1993-2013 were selected from the Cryo On-Line Data Registry for a 1:1 matched comparison between those undergoing whole - gland and partial prostate cryotherapy (targeted-ablation, unilateral/bilateral nerve-sparing ablations). A propensity score was developed based on age, pre-biopsy serum PSA, biopsy Gleason score, clinical stage, prostate volume, neoadjuvant androgen deprivation status, year of surgery and pre-treatment potency. Outcomes were biochemical progression-free survival (BPFS) using ASTRO and Phoenix criteria, 12-month continence (strictly pad-free) and sexual function (potency sufficient for sexual intercourse). After propensity score - matching, BPFS was compared using Kaplan-Meier analysis and functional outcomes using chi-square tests. In all, 897 men were identified (731 whole - gland and 166 partial). Post-matching, 166 pairs of men were analysed (mean follow-up 31 months). The 2/5 year BPFS rate was 87.2%/76.4% for whole - gland vs. 80.7%/70.0% for partial ablation using Phoenix (p=0.26) and 72.3%/69.6% for whole gland vs. 82.1%/75.0% for partial ablation using ASTRO criteria (p=0.10). Of 164 pairs, the 12-month continence rate was similar 94.1% vs. 95.1% (p=0.803). Of 139 pairs, the 12-month rate of successful intercourse was 29.5% for whole - gland and 46.8% for partial ablation (OR 2.1, p=0.003). The incidence of post-treatment urinary retention was 6.0% and 6.6% (p=0.88) following whole - gland and partial ablation respectively and that of rectourethral fistula was 1.2% and 0% (p=0.50) Conclusion: Partial ablation results in better post-treatment sexual function compared to whole - gland ablation in men with intermediate-risk prostate cancer. We did not observe a difference in early BPFS between the two groups.
28385075	0	16	Propensity Score	T081	C2718044
28385075	25	35	Comparison	T052	C1707455
28385075	39	46	Partial	T081	C0728938
28385075	50	55	Whole	T081	C0444667
28385075	56	61	Gland	T023	C0033572
28385075	62	73	Cryotherapy	T061	C3544233
28385075	78	95	Intermediate-Risk	T033	C3640764
28385075	96	111	Prostate Cancer	T191	C0376358
28385075	116	124	analysis	T062	C0936012
28385075	132	150	COLD registry data	T170	C0282574
28385075	166	177	oncological	T191	C0027651
28385075	182	192	functional	T169	C0205245
28385075	193	201	outcomes	T080	C0085415
28385075	205	212	partial	T081	C0728938
28385075	220	225	whole	T081	C0444667
28385075	228	233	gland	T023	C0033572
28385075	234	245	cryotherapy	T061	C3544233
28385075	250	253	men	T098	C0025266
28385075	259	276	intermediate-risk	T033	C3640764
28385075	277	292	prostate cancer	T191	C0376358
28385075	294	297	Men	T098	C0025266
28385075	303	320	intermediate-risk	T033	C3640764
28385075	321	336	prostate cancer	T191	C0376358
28385075	337	349	treated with	T061	C0332293
28385075	350	357	primary	T080	C0205225
28385075	358	378	prostate cryotherapy	T061	C3544233
28385075	417	443	Cryo On-Line Data Registry	T170	C0282574
28385075	454	461	matched	T062	C0150103
28385075	462	472	comparison	T052	C1707455
28385075	498	503	whole	T081	C0444667
28385075	506	511	gland	T023	C0033572
28385075	516	523	partial	T081	C0728938
28385075	524	544	prostate cryotherapy	T061	C3544233
28385075	546	563	targeted-ablation	T061	C0547070
28385075	565	609	unilateral/bilateral nerve-sparing ablations	T061	C0547070
28385075	614	630	propensity score	T081	C2718044
28385075	654	657	age	T032	C0001779
28385075	659	675	pre-biopsy serum	T031	C0229671
28385075	676	679	PSA	T116,T126,T129	C0138741
28385075	681	701	biopsy Gleason score	T033	C2123503
28385075	703	717	clinical stage	T079	C0205563
28385075	719	734	prostate volume	T081	C1441416
28385075	736	768	neoadjuvant androgen deprivation	T061	C1515985
28385075	769	775	status	T080	C0449438
28385075	777	781	year	T079	C0439234
28385075	785	792	surgery	T061	C0543467
28385075	797	810	pre-treatment	T079	C2709094
28385075	820	828	Outcomes	T080	C0085415
28385075	834	845	biochemical	T170	C3897727
28385075	846	871	progression-free survival	T081	C0242792
28385075	873	877	BPFS	T081	C0242792
28385075	885	890	ASTRO	T170	C0935549
28385075	895	911	Phoenix criteria	T170	C0935549
28385075	922	932	continence	T040	C0542565
28385075	957	972	sexual function	T040	C0278092
28385075	982	992	sufficient	T080	C0205410
28385075	997	1015	sexual intercourse	T040	C0009253
28385075	1024	1040	propensity score	T081	C2718044
28385075	1043	1051	matching	T062	C0150103
28385075	1053	1057	BPFS	T081	C0242792
28385075	1062	1070	compared	T052	C1707455
28385075	1077	1098	Kaplan-Meier analysis	T081	C1720943
28385075	1103	1113	functional	T169	C0205245
28385075	1114	1122	outcomes	T080	C0085415
28385075	1129	1145	chi-square tests	T170	C0008041
28385075	1159	1162	men	T098	C0025266
28385075	1168	1178	identified	T080	C0205396
28385075	1184	1189	whole	T081	C0444667
28385075	1192	1197	gland	T023	C0033572
28385075	1206	1213	partial	T081	C0728938
28385075	1216	1229	Post-matching	T079	C1254367
28385075	1244	1247	men	T098	C0025266
28385075	1253	1261	analysed	T062	C0936012
28385075	1268	1277	follow-up	T058	C1522577
28385075	1303	1307	BPFS	T081	C0242792
28385075	1308	1312	rate	T081	C1521828
28385075	1333	1338	whole	T081	C0444667
28385075	1341	1346	gland	T023	C0033572
28385075	1367	1374	partial	T081	C0728938
28385075	1375	1383	ablation	T061	C0547070
28385075	1390	1397	Phoenix	T170	C0935549
28385075	1427	1432	whole	T081	C0444667
28385075	1433	1438	gland	T023	C0033572
28385075	1459	1466	partial	T081	C0728938
28385075	1467	1475	ablation	T061	C0547070
28385075	1482	1487	ASTRO	T170	C0935549
28385075	1534	1544	continence	T040	C0542565
28385075	1545	1549	rate	T081	C1521828
28385075	1554	1561	similar	T080	C2348205
28385075	1624	1634	successful	T080	C1272703
28385075	1635	1646	intercourse	T040	C0009253
28385075	1661	1666	whole	T081	C0444667
28385075	1669	1674	gland	T023	C0033572
28385075	1689	1696	partial	T081	C0728938
28385075	1697	1705	ablation	T061	C0547070
28385075	1729	1738	incidence	T081	C0021149
28385075	1742	1756	post-treatment	T079	C2709088
28385075	1757	1774	urinary retention	T033	C0080274
28385075	1812	1817	whole	T081	C0444667
28385075	1820	1825	gland	T023	C0033572
28385075	1830	1837	partial	T081	C0728938
28385075	1838	1846	ablation	T061	C0547070
28385075	1872	1893	rectourethral fistula	T047	C0268875
28385075	1931	1938	Partial	T081	C0728938
28385075	1939	1947	ablation	T061	C0547070
28385075	1948	1955	results	T033	C0808233
28385075	1959	1965	better	T080	C0332272
28385075	1966	1980	post-treatment	T079	C2709088
28385075	1981	1996	sexual function	T040	C0278092
28385075	1997	2005	compared	T052	C1707455
28385075	2009	2014	whole	T081	C0444667
28385075	2017	2022	gland	T023	C0033572
28385075	2023	2031	ablation	T061	C0547070
28385075	2035	2038	men	T098	C0025266
28385075	2044	2061	intermediate-risk	T033	C3640764
28385075	2062	2077	prostate cancer	T191	C0376358
28385075	2114	2119	early	T079	C1279919
28385075	2120	2124	BPFS	T081	C0242792
28385075	2141	2147	groups	T078	C0441833